Researcher:
Selçukbiricik, Fatih

Profile Picture
ORCID

Job Title

Faculty Member

First Name

Fatih

Last Name

Selçukbiricik

Name

Name Variants

Selçukbiricik, Fatih

Email Address

Birth Date

Filters

2010 - 2019162020 - 202327

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.50b62211-6219-4df7-abf0-9d58b403e9ea

Search Results

Now showing 1 - 10 of 44
  • Placeholder
    PublicationMetadata only
    Prognostic significance of metastatic lymph node ratio in patients with pN3 gastric cancer who underwent curative gastrectomy
    (Karger, 2019) Bilici, Ahmet; Şeker, Mesut; Öven, Basak B.; Ölmez, Ömer Fatih; Yıldız, Özcan; Ölmüşçelik, Oktay; Hamdard, Jamshid; Açıkgöz, Özgür; Çakır, Aslı; Öncel, Mustafa; Selçukbiricik, Fatih; Kapran, Yersu; Balık, Emre; Faculty Member; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; 202015; 168101; 18758
    Background: Lymph node involvement is an important prognostic factor in patients with gastric cancer. The aim of this study was to determine the prognostic significance of metastatic lymph node ratio (MLNR) and compare it to the number of lymph node metastasis in pN3 gastric cancer. Methods: We retrospectively analyzed 207 patients with pN3 gastric cancer who had undergone radical gastrectomy. Prognostic factors and MLNR were evaluated by univariate and multivariate analysis. Results: An MLNR of 0.75 was found to be the best cut-off value to determine the prognosis of patients with pN3 gastric cancer (p = 0.001). The MLNR was significantly higher in patients with large-sized and undifferentiated tumors, vascular, lymphatic and perineural invasion, and total gastrectomy. In multivariate analysis, MLNR (p = 0.041), tumor differentiation (p = 0.046), and vascular invasion (p = 0.012) were found to be independent prognos-tic factors for disease-free survival, while both MLNR (p < 0.001) and pN stage (p = 0.002) were independent prognostic indicators, as was tumor size, for overall survival. There was significant difference with respect to the recurrence patterns between MLNR groups. Lymph node and peritoneal recurrences were significantly higher in patients with MLNR > 0.75 compared to the MLNR < 0.75 group (p < 0.05). However, recurrence patterns were similar between pN3a and pN3b. Conclusion: Our results showed that MLNR was a useful indicator to determine the prognosis and recurrence patterns of patients with radically resected gastric cancer. Moreover, MLNR is a beneficial and reliable technique for evaluating lymph node metastasis.
  • Placeholder
    PublicationMetadata only
    Comparison of surgical methods in patients receiving neoadjuvant treatment; thoracoscopy vs. thoracotomy
    (Elsevier Science Inc, 2022) Özer, K. B.; Mandel, NM; Dilege, S; N/A; N/A; Erus, Suat; Selçukbiricik, Fatih; Tanju, Serhan; Faculty Member; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; 202015; 214690
    N/A
  • Placeholder
    PublicationMetadata only
    Is alveolar spread may be predictive with PET CT scanning?
    (Elsevier Science inc, 2017) Zeren, Handan; Selçukbiricik, Fatih; Mandel, Nil Molinas; Tanju, Serhan; Falay, Fikri Okan; Bulutay, Pınar; Zeren, Emine Handan; Erus, Suat; Dilege, Şükrü; Faculty Member; Faculty Member; Faculty Member; Teaching Faculty; Teaching Faculty; N/A; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; 202015; 194197; 214690; 246484; 133565; N/A; 175565; 22573
    Background: In this study we aim to investigate predictability of alveolar spread in primary lung cancer by using preoperatively scanning methods. Method: In order to re-evaluate alveolar spread, pathology preparations of 45 patients had operated for primary lung cancer diagnosis and scanned preoperatively with PET CT all in our hospital which interpreted by same nuclear medicine specialists implicated in this study. As using the patients pet CT findings, CTV (computerized tomography volume), MTV (metabolic tumor volume), TLG(total lesion glycolysis), SUDmax, SUDort values and their relation with alveolar spread analyzed. Result: Preoperatively PET-CT scanned all in our hospital 45 patients has included and cause of couldn't reach their pathological preparations, 6 of them exluded from the study. 21 of 39 patients were men (53.8%) , 18 of them were women (46.2%) and mean age was 66.67/+-7.88 (42-80). We didn't detect any relation between CTV, MTV, TLG, SUDmax, SUDort values and alveolar spread (p>0.05). However when the CTV/ MTV ratio analyzed, alveolar spread was statistically more common in the group of patients had ratio lower than 1. (62.9% versus 0%, p:0.01). Conclusion: High local recurrence risk in sublober rejected patients with alveolar spread has indicated in various studies. Regarding this matter, we recommend re-evaluation of the patients for sublober rejections whose CTV/MTV ratio is lower than 1.
  • Placeholder
    PublicationMetadata only
    Palliative care needs of the cancer patients receiving active therapy
    (Springer, 2022) Bağçivan, Gülcan; Seven, Memnun; Selçukbiricik, Fatih; Paşalak, Şeyma İnciser; Bilmiç, Ezgi; Tabak, Levent; Faculty Member; Faculty Member; Faculty Member; PhD Student; Master Student; N/A; N/A; Faculty Member; School of Nursing; School of Nursing; School of Medicine; Graduate School of Health Sciences; Graduate School of Health Sciences; N/A; N/A; School of Medicine; 261422; 32470; 202015; 125009; N/A; N/A; N/A; 167625
    Purpose To identify cancer patients' palliative care needs with problem burden, problem intensity, and felt needs related to these problems while receiving cancer treatment. Methods This is a descriptive survey study conducted at a tertiary hospital with no palliative care services in Istanbul, Turkey, from September 2019 to February 2020. Data were collected using the Patient Information Form and the Three Levels of Needs Questionnaire (3LNQ). Descriptive statistics (frequency and percentage) were used to present data. Results The mean age of patients was 60.2 +/- 13.0, and the mean duration since the diagnosis was 11.6 +/- 21.4 months. Of the patients, 40.4% were diagnosed with gastrointestinal (GI) cancer, and 34.4% had stage 4 cancer. Patients mostly received help for their pain (85.7%), lack of appetite (64.8%), and nausea (73/7%). The most frequent unmet needs were problems with concentration (70%), worrying (68%), difficulties with sex life (63.6%), problems with being limited in work and daily activities (61.4%), and being depressed (58.5%) among patients who reported to have these symptoms. Conclusion This study shows that patients with cancer require supportive and palliative care along with medical treatment for cancer and its treatment-induced physical and psychological symptoms. The study results have the potential to guide the development of palliative care services, especially for outpatient oncology settings in countries where palliative care services mostly focus on the end-of-life care. Further studies are also needed to focus on interventions to meet cancer patients' palliative care needs during the medical cancer treatment process with tailored palliative care delivery models.
  • Placeholder
    PublicationMetadata only
    Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: a real-life data of Turkish Oncology Group
    (Lippincott Williams and Wilkins (LWW), 2022) Gurbuz, Mustafa; Kilickap, Saadettin; Bilici, Ahmet; Karadurmus, Nuri; Sezer, Ahmet; Sendur, Mehmet Ali Nahit; Paydas, Semra; Artac, Mehmet; Gursoy, Pinar; Uysal, Mukremin; Senol Coskun, Hasan; Tatli, Ali Murat; Disel, Umut; Koksoy, Elif Berna; Guven, Deniz Can; Ugrakli, Muzaffer; Akkus, Erman; Yucel, Sebnem; Erol, Cihan; Karakaya, Serdar; Sakalar, Teoman; Khanmammadov, Nijat; Paksoy, Nail; Demirkazik, Ahmet; N/A; Yumuk, Perran Fulden; Selçukbiricik, Fatih; Other; Faculty Member; School of Medicine; School of Medicine; Koç University Hospital; N/A; 202015
    Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterations, there is limited real-life data. Aim of this study is to investigate real-life efficacy and safety of crizotinib in patients with advanced NSCLC harboring MET alterations. This was a retrospective, multicenter (17 centers) study of Turkish Oncology Group. Patients' demographic, histological data, treatment, response rates, survival outcomes, and toxicity data were collected. Outcomes were presented for the study population and compared between MET alteration types. Total of 62 patients were included with a median age of 58.5 (range, 26-78). Major histological type was adenocarcinoma, and 3 patients (4.8%) had sarcomatoid component. The most common MET analyzing method was next generation sequencing (90.3%). MET amplification and mutation frequencies were 53.2% (n = 33) and 46.8% (n = 29), respectively. Overall response rate and disease control rate were 56.5% and 74.2% in whole study population, respectively. Median progression free survival (PFS) was 7.2 months (95% confidence interval [CI]: 3.8-10.5), and median overall survival (OS) was 18.7 months (95% CI: 13.7-23.7), regardless of treatment line. Median PFS was 6.1 months (95% CI: 5.6-6.4) for patients with MET amplification, whereas 14.3 months (95% CI: 6.7-21.7) for patients with MET mutation (P = .217). Median PFS was significantly longer in patients who have never smoked (P = .040), have good performance score (P < .001), and responded to the treatment (P < .001). OS was significantly longer in patients with MET mutation (25.6 months, 95% CI: 15.9-35.3) compared to the patients with MET amplification (11.0 months; 95% CI: 5.2-16.8) (P = .049). In never-smokers, median OS was longer than smoker patients (25.6 months [95% CI: 11.8-39.3] vs 16.5 months [95% CI: 9.3-23.6]; P = .049). The most common adverse effects were fatigue (50%), peripheral edema (21%), nausea (29%) and diarrhea (19.4%). Grade 3 or 4 adverse effects were observed in 6.5% of the patients. This real-life data confirms efficacy and safety of crizotinib in the treatment of advanced NSCLC harboring MET alteration.
  • Placeholder
    PublicationMetadata only
    Evaluation of sarcopenia, malnutrition and nutritional status of patients with and without cancer treatment by age
    (İstanbul Ünivrsitesi, 2022) Aytulu, Tuğçe; Çalıkoğlu, Fulya; İşsever, Halim; Satman, İlhan; Selçukbiricik, Fatih; Çan, Meltem Yılmaz; Ergene, Gözde; Faculty Member; Doctor; Doctor; School of Medicine; N/A; N/A; Koç University Hospital; Koç University Hospital; 202015; N/A; N/A
    Objective: The aim of this study is to evaluate patients who are just starting or have started chemotherapy and also who are geriatric and nongeriatric, of sarcopenia and nutritional status. Materials and Methods: In this study, adult cancer patients who will receive chemotherapy for the first time were evaluated in terms of sarcopenia and nutritional status with patients between the 3rd month and 1st year of chemotherapy treatment. Patients were compared according to whether they were geriatric or not, and sarcopenic patients were also evaluated by classifying them according to cancer sides. The patients’ hand grip strength, bioelectrical impedance, appendicular skeletal muscle index (corrected for height), walking speed were measured and evaluated for sarcopenia. In addition, malnutrition risks, three-day food consumption records and laboratory parameters were examined. Results: A total of 123 adult patients were evaluated and 58 (47.2%) of the patients in the study were geriatric (65 years ≥). The risk of malnutrition was high in 39% of the patients and was found to be significantly higher in the geriatric group (46.6%) than in the non-geriatric group (32.3%) (p=0.029). The risk of malnutrition was found to be associated with the diagnosis groups of cancer. Compared to breast cancer, the risk of malnutrition was 18.2 times (p=0.002) higher in hepatobiliary cancers (including pancreas) and 7.6 times (p=0.018) in other cancers (head and neck, sarcoma, brain, stomach, peritoneum). Conclusion: Especially in geriatric patients, it is important to recognize and evaluate malnutrition caused by cancer at the beginning of treatment. / Amaç: Kemoterapiye yeni başlayacak veya başlamış olan, geriatrik olan ve olmayan hastalarda sarkopeninin ve beslenme durumunun değerlendirilmesidir. Gereç ve Yöntem: Bu çalışmada, ilk kez kemoterapi alacak yetişkin kanser hastalar, kemoterapi tedavisinin 3.ayı ile 1.yılı arasında olan hastalarla sarkopeni yönünden ve beslenme durumları açısından değerlendirilmiştir. Hastaların geriatrik olup olmamasına göre karşılaştırılmış ve ayrıca sarkopenik olan hastalar kanser türlerine göre sınıflandırılarak da değerlendirilmiştir. Hastaların el kavrama kuvvetleri, biyoelektrik impedans ile apendiküler iskelet kas indeksi (boya göre düzeltilmiş), yürüme hızları ölçülmüş ve sarkopenik düzeyleri, malnütrisyon riskleri, üç günlük besin tüketim kayıtları ve laboratuvar parametreleri incelenmiştir. Bulgular: Toplamda 123 yetişkin hasta değerlendirilmiştir. Çalışmadaki hastaların 58’i (%47,2’si) geriatriktir (65 yaş ≥) ve %39’unun malnütrisyon riski yüksektir. Geriatrik olan grupta (%46,6) olmayanlara göre (%32,3) anlamlı derecede malnütrisyon riski yüksek bulunmuştur (p=0,029). Malnütrisyon riski kanserin tanı gruplarıyla da ilişkili bulunmuştur. Meme kanserine göre, malnütrisyon riskinin hepatobiliyer kanserlerde (pankreas dahil) 18,2 kat (p=0,002) ve diğer kanserlerde (baş-boyun, sarkom, beyin, mide, periton) 7,6 kat (p=0,018) daha yüksek olduğu görülmüştür. Sonuç: Özellikle geriatrik hastalarda, kanserin neden olduğu malnütrisyonun, tedavinin başlangıcında farkedilmesi ve değerledirilmesi önemlidir.
  • Placeholder
    PublicationMetadata only
    A mobile application for symptom management in patients with breast cancer
    (Oncology Nursing Society, 2022) Seven M.; N/A; N/A; Department of Computer Engineering; N/A; Paşalak, Şeyma İnciser; Bağçivan, Gülcan; Özkasap, Öznur; Selçukbiricik, Fatih; PhD Student; Faculty Member; Faculty Member; Faculty Member; Department of Computer Engineering; Graduate School of Health Sciences; School of Nursing; College of Engineering; School of Medicine; 125009; 261422; 113507; 202015
    OBJECTIVES: To evaluate the effect of a symptom management mobile application on quality of life and symptom severity in women with breast cancer undergoing chemotherapy. SAMPLE & SETTING: This parallel randomized pilot study consisted of women with breast cancer admitted to oncology outpatient clinics between November 2019 and January 2021 in Turkey. METHODS & VARIABLES: Participants (N = 40) were randomly assigned to the intervention (n = 20) or control group (n = 20). The intervention group used the mobile application in conjunction with usual care. The control group received usual care. Participants were assessed during the first, third, and last chemotherapy cycles. Data were collected using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire–Core 30 and the Edmonton Symptom Assessment System. RESULTS: During the study, the decrease in general health and physical functioning and the increase in the severity of depression/sadness in the intervention group were statistically lower than in the control group. IMPLICATIONS FOR NURSING: The use of a mobile application for symptom management may promote general well-being and physical function and may alleviate symptoms of depression/sadness in women with breast cancer undergoing chemotherapy. Further studies are needed to evaluate the application in clinical settings with larger groups.
  • Placeholder
    PublicationMetadata only
    Outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical treatment
    (Elsevier Science Inc, 2017) Bilici, A.; Rzazade, R.; Ölmez, O. F.; Çağlar, H. B.; Yıldız, O.; Selçukbiricik, Fatih; Faculty Member; School of Medicine; Koç University Hospital; 202015
    N/A
  • Placeholder
    PublicationMetadata only
    Low regrowth after cCR in non-operative TNT management of locally advanced rectal cancer patients
    (Elsevier Ireland Ltd, 2022) N/A; N/A; N/A; N/A; N/A; N/A; N/A; Selek, Uğur; Selçukbiricik, Fatih; Özoran, Emre; Balık, Emre; Bölükbaşı, Yasemin; Mandel, Nil Molinas; Buğra, Dursun; Faculty Member; Faculty Member; Teaching Faculty; Faculty Member; Faculty Member; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; 27211; 202015; 307296; 18758; 216814; 194197; 1758
    N/A
  • Placeholder
    PublicationMetadata only
    Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study
    (Lippincott Williams and Wilkins (LWW), 2021) Tacar, Seher Yıldız; Yılmaz, Mesut; Sarıcı, Ahmet Murat; Gültürk, İlkay; Ayhan, Murat; Tural, Deniz; Selçukbiricik, Fatih; Ertürk, Kayhan; Faculty Member; Faculty Member; School of Medicine; School of Medicine; 202015; N/A
    Systemic treatment options with proven efficacy for the treatment of metastatic uveal melanoma are limited. In this study, we aimed to evaluate the efficacy of nivolumab in metastatic uveal melanoma patients. In our multi-center study, the files of patients who received nivolumab treatment with a diagnosis of metastatic uveal melanoma were retrospectively reviewed and their information was recorded. Seventeen patients were enrolledand 16 patients were evaluable for efficacy. The objective response rate (ORR) was 18% including one confirmed complete response and two confirmed partial responses. The median progression-free survival (PFS) was 5.8 months (95% CI, 0.03-11.57 months), and the median overall survival (OS) was 10.5 months (95% CI, 3.87-14.14 months). Significant longer OS and PFS were observed in patients with the performance status of the Eastern Cooperative Oncology Group (ECOG-PS) 0. Although significant longer OS was detected in patients with low median lactate dehydrogenase (LDH) levels, no significant difference was found in PFS. Grade 1 and 2 fatigue and decreased appetite were the most common side effects associated with treatment (17%); grade 3 and 4 side effects were not observed. Immunotherapy is also emerging as a treatment option among the limited number of treatment options in metastatic uveal melanoma (mUM), but its efficacy needs to be demonstrated with prospective studies involving a larger number of patients.